Anti-vascular Endothelial Growth Factor (VEGF) Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2025-2034

The Global Anti-vascular Endothelial Growth Factor (VEGF) Therapeutics Market was valued at USD 16.9 billion in 2024 and is estimated to grow at a CAGR of 5.2% to reach USD 28.6 billion by 2034.

Market growth is driven by the rising prevalence of retinal disorders such as age-related macular degeneration (AMD), diabetic retinopathy, macular edema, and retinal vein occlusion. Anti-VEGF therapies have become the gold standard for managing vision-threatening ophthalmic conditions by inhibiting abnormal blood vessel growth and vascular leakage in the retina. The expanding aging population, increasing diabetes burden, and growing awareness regarding early diagnosis and timely treatment of eye diseases are significantly boosting demand. In addition, technological advancements in biologics development, sustained-release drug delivery systems, and longer-acting formulations are improving treatment outcomes while reducing injection frequency, thereby enhancing patient compliance and long-term disease management.

Based on anti-VEGF therapies, the Eylea segment generated USD 9.7 billion in 2024, owing to its strong clinical efficacy, extended dosing intervals, and widespread physician preference for treating wet AMD, diabetic macular edema, and diabetic retinopathy. Eylea’s ability to deliver consistent vision stabilization with fewer injections has made it a cornerstone therapy across developed healthcare markets. Recent advancements, including higher-dose formulations, further strengthen its competitive position by addressing treatment burden, a key challenge in chronic retinal disease management. The growing number of ophthalmology clinics, expanding reimbursement coverage, and strong real-world clinical evidence continue to support sustained adoption of Eylea globally.

By drug type, the biologics segment accounted for USD 15.7 billion in 2024. Innovator biologics such as aflibercept, ranibizumab, and faricimab dominate prescribing patterns due to their proven safety profiles, established regulatory approvals, and inclusion in standard clinical treatment guidelines. These biologics are widely used across multiple indications, including AMD, diabetic retinopathy, and retinal vein occlusion, supporting their strong revenue contribution. Although biosimilars are gaining traction due to cost advantages, biologics continue to lead the market as physicians prioritize long-term efficacy, durability, and clinical familiarity in vision-critical treatments.

North America Anti-vascular Endothelial Growth Factor (VEGF) Therapeutics Market held 64.8% share in 2024, supported by advanced healthcare infrastructure, high disease prevalence, and early adoption of innovative ophthalmic biologics. The region benefits from strong reimbursement frameworks, a large aging population, and a high concentration of ophthalmology specialists and retina care centers. Regulatory support for novel formulations, along with increased screening programs for diabetic eye diseases and AMD, further strengthens market growth. The presence of leading pharmaceutical companies and ongoing clinical research activity positions North America as the dominant hub for anti-VEGF therapy adoption.

Key players operating in the Global Anti-VEGF Therapeutics Market include Regeneron Pharmaceuticals, Roche, Novartis, AMGEN, Biocon Biologics, Biogen, CELLTRION, Intas Pharmaceuticals, Lupin, Sandoz, STADA, Teva, Reliance Life Sciences, Astellas, and KANGHONG Pharmaceuticals. These companies compete through strong product portfolios, robust clinical pipelines, and expanding global distribution networks. Companies in the Anti-VEGF Therapeutics Market are strengthening their market foothold through continuous innovation in long-acting formulations, sustained-release delivery systems, and next-generation biologics aimed at reducing injection frequency. Strategic development and commercialization of biosimilars are helping players improve affordability and expand patient access, particularly in cost-sensitive regions. Leading firms are also focusing on regulatory approvals and geographic expansion, especially across Asia Pacific and Latin America. Show more